RQ Bio, a private biotechnology company developing long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations, has completed an oversubscribed US$115m (£85.5m) Series A financing. The financing was led by Frazier Life Sciences, with participation from new investors EQT Life Sciences, Forbion, Monograph and Wellington Management alongside founding investor LifeArc Ventures, as well as shareholders Oxford Science Enterprises and the University of Oxford.
The Company’s lead programme, RQB01, currently in IND-enabling studies, is designed to deliver potent and broad protection against influenza through a differentiated dual mechanism of action targeting conserved epitopes resilient to seasonal variation.
“This financing will support clinical development of RQB01 as well as advance our proprietary antibody discovery approach towards a pipeline of assets for prophylaxis of respiratory viral diseases,” said Mike Westby, CEO of RQ Bio.
